Feasible# yes/no | Patients | Hospitals | |
Tier 1 | |||
Mortality | Yes (100) | 509/509 | 6/6 |
Pulmonary function | Yes (100) | 509/509 | 6/6 |
sIL-2R change as an activity biomarker | No (16.5) | 84/509 | 1/6¶ |
Tier 2 | |||
Weight gain | Yes (81) | 412/509 | 5/6 |
Tier 3 | |||
Quality of life; physical functioning | No (0) | 0/0 | 0/6 |
Osteoporosis | nm | nm | 6/6+ |
COS | Yes (81) | 412/509 | 5/6 |
Data are presented as n or n (%), unless otherwise stated. sIL-2R: soluble interleukin-2 receptor; COS: clinical outcome status; nm: not measurable. #: the outcome measure was considered feasible when this was measured in >80% of all patients; ¶: sIL-2R was feasible in St Antonius Hospital (it was measured in 84% of the patients), but in the other centres it was not routinely measured; +: all centres make use of a local protocol to prevent osteopenia/osteoporosis in high-risk patients (in patients with long-term and/or high-dose prednisone use).